GB1302471A - - Google Patents
Info
- Publication number
- GB1302471A GB1302471A GB175471A GB175471A GB1302471A GB 1302471 A GB1302471 A GB 1302471A GB 175471 A GB175471 A GB 175471A GB 175471 A GB175471 A GB 175471A GB 1302471 A GB1302471 A GB 1302471A
- Authority
- GB
- United Kingdom
- Prior art keywords
- jan
- active ingredient
- drug
- enhanced
- weight
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Expired
Links
- 239000003814 drug Substances 0.000 abstract 3
- VLKZOEOYAKHREP-UHFFFAOYSA-N n-Hexane Chemical compound CCCCCC VLKZOEOYAKHREP-UHFFFAOYSA-N 0.000 abstract 3
- 239000004480 active ingredient Substances 0.000 abstract 2
- ZYGHJZDHTFUPRJ-UHFFFAOYSA-N coumarin Chemical compound C1=CC=C2OC(=O)C=CC2=C1 ZYGHJZDHTFUPRJ-UHFFFAOYSA-N 0.000 abstract 2
- 229940079593 drug Drugs 0.000 abstract 2
- -1 e.g. Substances 0.000 abstract 2
- WJFKNYWRSNBZNX-UHFFFAOYSA-N 10H-phenothiazine Chemical compound C1=CC=C2NC3=CC=CC=C3SC2=C1 WJFKNYWRSNBZNX-UHFFFAOYSA-N 0.000 abstract 1
- LTMHDMANZUZIPE-UHFFFAOYSA-N 3-[3-[5-[5-(4,5-dihydroxy-6-methyloxan-2-yl)oxy-4-hydroxy-6-methyloxan-2-yl]oxy-4-hydroxy-6-methyloxan-2-yl]oxy-12,14-dihydroxy-10,13-dimethyl-1,2,3,4,5,6,7,8,9,11,12,15,16,17-tetradecahydrocyclopenta[a]phenanthren-17-yl]-2h-furan-5-one Chemical compound C1C(O)C(O)C(C)OC1OC1C(C)OC(OC2C(OC(OC3CC4C(C5C(C6(CCC(C6(C)C(O)C5)C=5COC(=O)C=5)O)CC4)(C)CC3)CC2O)C)CC1O LTMHDMANZUZIPE-UHFFFAOYSA-N 0.000 abstract 1
- KXDHJXZQYSOELW-UHFFFAOYSA-M Carbamate Chemical compound NC([O-])=O KXDHJXZQYSOELW-UHFFFAOYSA-M 0.000 abstract 1
- 229910002651 NO3 Inorganic materials 0.000 abstract 1
- 239000004098 Tetracycline Substances 0.000 abstract 1
- 229940121792 Thiazide diuretic Drugs 0.000 abstract 1
- 238000010521 absorption reaction Methods 0.000 abstract 1
- 230000000202 analgesic effect Effects 0.000 abstract 1
- 239000003242 anti bacterial agent Substances 0.000 abstract 1
- 230000003276 anti-hypertensive effect Effects 0.000 abstract 1
- 239000003146 anticoagulant agent Substances 0.000 abstract 1
- 229940127219 anticoagulant drug Drugs 0.000 abstract 1
- 229940124976 antitubercular drug Drugs 0.000 abstract 1
- 229940125717 barbiturate Drugs 0.000 abstract 1
- HNYOPLTXPVRDBG-UHFFFAOYSA-N barbituric acid Chemical compound O=C1CC(=O)NC(=O)N1 HNYOPLTXPVRDBG-UHFFFAOYSA-N 0.000 abstract 1
- 230000003115 biocidal effect Effects 0.000 abstract 1
- 229920001400 block copolymer Polymers 0.000 abstract 1
- 230000000747 cardiac effect Effects 0.000 abstract 1
- 229960005091 chloramphenicol Drugs 0.000 abstract 1
- WIIZWVCIJKGZOK-RKDXNWHRSA-N chloramphenicol Chemical compound ClC(Cl)C(=O)N[C@H](CO)[C@H](O)C1=CC=C([N+]([O-])=O)C=C1 WIIZWVCIJKGZOK-RKDXNWHRSA-N 0.000 abstract 1
- 239000003246 corticosteroid Substances 0.000 abstract 1
- 229960000956 coumarin Drugs 0.000 abstract 1
- 235000001671 coumarin Nutrition 0.000 abstract 1
- 239000000262 estrogen Substances 0.000 abstract 1
- 229940011871 estrogen Drugs 0.000 abstract 1
- 230000002496 gastric effect Effects 0.000 abstract 1
- 230000002218 hypoglycaemic effect Effects 0.000 abstract 1
- 239000000041 non-steroidal anti-inflammatory agent Substances 0.000 abstract 1
- 239000008194 pharmaceutical composition Substances 0.000 abstract 1
- 229950000688 phenothiazine Drugs 0.000 abstract 1
- 238000001179 sorption measurement Methods 0.000 abstract 1
- 230000003637 steroidlike Effects 0.000 abstract 1
- YROXIXLRRCOBKF-UHFFFAOYSA-N sulfonylurea Chemical compound OC(=N)N=S(=O)=O YROXIXLRRCOBKF-UHFFFAOYSA-N 0.000 abstract 1
- 229960002180 tetracycline Drugs 0.000 abstract 1
- 229930101283 tetracycline Natural products 0.000 abstract 1
- 235000019364 tetracycline Nutrition 0.000 abstract 1
- 150000003522 tetracyclines Chemical class 0.000 abstract 1
- 239000003451 thiazide diuretic agent Substances 0.000 abstract 1
- 229940125725 tranquilizer Drugs 0.000 abstract 1
- 239000003204 tranquilizing agent Substances 0.000 abstract 1
- 230000002936 tranquilizing effect Effects 0.000 abstract 1
- 239000000083 urinary anti-infective agent Substances 0.000 abstract 1
- 229940124549 vasodilator Drugs 0.000 abstract 1
- 239000003071 vasodilator agent Substances 0.000 abstract 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
- A61K9/4841—Filling excipients; Inactive ingredients
- A61K9/4858—Organic compounds
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/16—Amides, e.g. hydroxamic acids
- A61K31/165—Amides, e.g. hydroxamic acids having aromatic rings, e.g. colchicine, atenolol, progabide
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
- A61K31/34—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having five-membered rings with one oxygen as the only ring hetero atom, e.g. isosorbide
- A61K31/343—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having five-membered rings with one oxygen as the only ring hetero atom, e.g. isosorbide condensed with a carbocyclic ring, e.g. coumaran, bufuralol, befunolol, clobenfurol, amiodarone
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
- A61K31/415—1,2-Diazoles
- A61K31/4152—1,2-Diazoles having oxo groups directly attached to the heterocyclic ring, e.g. antipyrine, phenylbutazone, sulfinpyrazone
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/60—Salicylic acid; Derivatives thereof
- A61K31/609—Amides, e.g. salicylamide
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/65—Tetracyclines
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
- A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
- A61K47/10—Alcohols; Phenols; Salts thereof, e.g. glycerol; Polyethylene glycols [PEG]; Poloxamers; PEG/POE alkyl ethers
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/20—Pills, tablets, discs, rods
- A61K9/2004—Excipients; Inactive ingredients
- A61K9/2022—Organic macromolecular compounds
- A61K9/2031—Organic macromolecular compounds obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyethylene glycol, polyethylene oxide, poloxamers
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
- A61K9/4841—Filling excipients; Inactive ingredients
- A61K9/4866—Organic macromolecular compounds
-
- C—CHEMISTRY; METALLURGY
- C08—ORGANIC MACROMOLECULAR COMPOUNDS; THEIR PREPARATION OR CHEMICAL WORKING-UP; COMPOSITIONS BASED THEREON
- C08L—COMPOSITIONS OF MACROMOLECULAR COMPOUNDS
- C08L71/00—Compositions of polyethers obtained by reactions forming an ether link in the main chain; Compositions of derivatives of such polymers
- C08L71/02—Polyalkylene oxides
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Epidemiology (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Polymers & Plastics (AREA)
- Organic Chemistry (AREA)
- Engineering & Computer Science (AREA)
- General Chemical & Material Sciences (AREA)
- Oil, Petroleum & Natural Gas (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US318870A | 1970-01-15 | 1970-01-15 | |
| US6727670A | 1970-08-26 | 1970-08-26 |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| GB1302471A true GB1302471A (enrdf_load_stackoverflow) | 1973-01-10 |
Family
ID=26671450
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| GB175471A Expired GB1302471A (enrdf_load_stackoverflow) | 1970-01-15 | 1971-01-13 |
Country Status (3)
| Country | Link |
|---|---|
| CA (1) | CA959759A (enrdf_load_stackoverflow) |
| FR (1) | FR2081436B1 (enrdf_load_stackoverflow) |
| GB (1) | GB1302471A (enrdf_load_stackoverflow) |
Cited By (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| GB2190838B (en) * | 1986-05-27 | 1990-12-12 | Sandoz Ltd | Pharmaceutical compositions |
| US5525355A (en) * | 1993-09-14 | 1996-06-11 | Euro-Celtique, S.A. | Laxative compositions |
Families Citing this family (10)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| GB1481411A (en) * | 1973-07-20 | 1977-07-27 | Scherer Ltd R | Pharmaceutical compositions |
| US4002718A (en) * | 1974-10-16 | 1977-01-11 | Arnar-Stone Laboratories, Inc. | Gelatin-encapsulated digoxin solutions and method of preparing the same |
| FR2500302B1 (fr) * | 1981-02-25 | 1985-11-15 | Negma Laboratoires | Nouvelles compositions pharmaceutiques d'indometacine |
| US5674911A (en) * | 1987-02-20 | 1997-10-07 | Cytrx Corporation | Antiinfective polyoxypropylene/polyoxyethylene copolymers and methods of use |
| WO1988006038A1 (en) * | 1987-02-20 | 1988-08-25 | Emory University | Antiinfective compounds and method of use |
| US5811088A (en) * | 1987-02-20 | 1998-09-22 | Emory University | Antiinfective compounds and methods of use |
| ES2037179T3 (es) * | 1987-11-25 | 1993-06-16 | American Cyanamid Company | Sistema de liberacion sostenida (controlada) para bloqueadores de canales de calcio de dihidropiridina. |
| US7202225B1 (en) | 1993-10-15 | 2007-04-10 | Emanuele R Martin | Therapeutic delivery compositions and methods of use thereof |
| US6933286B2 (en) | 1991-03-19 | 2005-08-23 | R. Martin Emanuele | Therapeutic delivery compositions and methods of use thereof |
| CA2106474C (en) * | 1991-03-19 | 2004-02-10 | R. Martin Emanuele | Polyoxypropylene/polyoxyethylene copolymers with improved biological activity |
Family Cites Families (3)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US3125491A (en) * | 1962-04-06 | 1964-03-17 | Chew able hematinic vitamin tablet | |
| US3365365A (en) * | 1965-08-09 | 1968-01-23 | Hoffmann La Roche | Repeat action pharmaceutical compositions in the form of discrete beadlets |
| FR2035770A1 (en) * | 1969-03-14 | 1970-12-24 | Orsymonde | Antispasmodic quercetin comp having - long lasting activity |
-
1971
- 1971-01-11 CA CA102,419A patent/CA959759A/en not_active Expired
- 1971-01-13 GB GB175471A patent/GB1302471A/en not_active Expired
- 1971-01-14 FR FR7101185A patent/FR2081436B1/fr not_active Expired
Cited By (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| GB2190838B (en) * | 1986-05-27 | 1990-12-12 | Sandoz Ltd | Pharmaceutical compositions |
| US5525355A (en) * | 1993-09-14 | 1996-06-11 | Euro-Celtique, S.A. | Laxative compositions |
Also Published As
| Publication number | Publication date |
|---|---|
| FR2081436A1 (enrdf_load_stackoverflow) | 1971-12-03 |
| FR2081436B1 (enrdf_load_stackoverflow) | 1974-08-30 |
| CA959759A (en) | 1974-12-24 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| FR2081436B1 (enrdf_load_stackoverflow) | ||
| RU94046044A (ru) | Новые 7 бета -замещенные 4-аза- 5 альфа -холестан-оны в качестве ингибиторов 5 альфа -редуктазы, фармацевтическая композиция на их основе, способ ее получения | |
| CA2302568A1 (en) | Method, compositions and kits for increasing the oral bioavailability of pharmaceutical agents | |
| ES461399A1 (es) | Procedimiento para preparar esteres de epinina con acidos carboxilicos de cadena ramificada. | |
| IE43693L (en) | Androstane derivatives | |
| ES465906A1 (es) | Un procedimiento de preparacion de comprimidos | |
| ATE15048T1 (de) | 4''-epi erythromycin a und seine derivate brauchbar wie antibakterielle mittel. | |
| US3144387A (en) | Anti-inflammatory compositions | |
| IE39443L (en) | Pharmaceutical compositions; 5-(substituted benzal)¹hydantoin derivatives | |
| GB1488995A (en) | Compositions containing anti-androgenic compounds | |
| GB1351437A (en) | N-substituted amino acids having antiviral anti-inflammatory or anti-tumour activity | |
| US3920809A (en) | Dibenzo(b,d)pyranone dispersions | |
| GB1511645A (en) | Sickle cell anaemia treatment | |
| GB1280290A (en) | Novel derivatives of benzhydrylpiperazine, their process of preparation and their therapeutic application | |
| IE903914A1 (en) | Pyrimidine biosynthesis inhibitors useful as¹immunosuppressive agents | |
| US4039668A (en) | Corticoid-containing inhalants | |
| GB1352392A (en) | Phenylisopropylamine derivatives | |
| GB1326528A (en) | Method of contraception and compositions used therein | |
| GB1219700A (en) | Pharmaceutical compositions comprising lincomycin derivatives | |
| US3316151A (en) | Methods and compositions for inducing tranquilizing, muscle relaxant and depressant activity | |
| IE45096L (en) | Thiadiazole derivatives | |
| US3703580A (en) | Antibacterial medicinal compositions | |
| GB1220793A (en) | Pharmaceutical compositions | |
| JPS63146839A (ja) | プテロシン系化合物を含んで成る制癌剤 | |
| IE37288B1 (en) | Pharmaceutical compositions for use in the treatment of certain respiratory diseases or conditions in prematurely born children |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| PS | Patent sealed | ||
| PCNP | Patent ceased through non-payment of renewal fee |